Anagrelide in essential thrombocythemia (ET)

被引：0
|
作者：
Peraino, M
Bizzoni, L
Bernasconi, S
Spadea, A
Russo, D
Cervellera, M
Mazzucconi, MG
机构：
[1] Univ La Sapienza, Dept Biotecnol Cellulari & Ematol, Roma, Italy
[2] Univ Udine, Dept Ric Med & Morfol, CI Ematol, I-33100 Udine, Italy
[3] Azienda Osped SS Annunziata, Unita Operat Ematol, Taranto, Italy
来源：
THROMBOSIS RESEARCH | 1998年 / 91卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
46
引用
收藏
页码：S25 / S26
页数：2
相关论文
共 50 条
  • [1] Anagrelide for essential thrombocythemia
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1997, 39 (1016): : 120 - 120
  • [2] Treatment of essential thrombocythemia with anagrelide
    Silverstein, MN
    Tefferi, A
    [J]. SEMINARS IN HEMATOLOGY, 1999, 36 (01) : 23 - 25
  • [3] TREATMENT OF ESSENTIAL THROMBOCYTHEMIA WITH ANAGRELIDE
    CHINTAGUMPALA, MM
    KENNEDY, LL
    STEUBER, CP
    [J]. JOURNAL OF PEDIATRICS, 1995, 127 (03): : 495 - 498
  • [4] Anagrelide hydrochloride for essential thrombocythemia
    Besses, Carles
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (12): : 1049 - 1062
  • [5] ADHERENCE SUPPORT PROGRAM FOR PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA (ET) TREATED WITH ANAGRELIDE
    Ramirez, G.
    Cardenes, J.
    Rejas, R.
    Plaza, S.
    Garcia-Ort, L.
    Navas, V.
    [J]. HAEMATOLOGICA, 2014, 99 : 669 - 669
  • [6] ESSENTIAL THROMBOCYTHEMIA IN A CHILD - MANAGEMENT WITH ANAGRELIDE
    CHINTAGUMPALA, MM
    STEUBER, CP
    MAHONEY, DH
    OGDEN, AK
    FERNBACH, DJ
    [J]. AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1991, 13 (01): : 52 - 56
  • [7] Anagrelide and Mutational Status in Essential Thrombocythemia
    Iurlo, Alessandra
    Cattaneo, Daniele
    Orofino, Nicola
    Bucelli, Cristina
    Fabris, Sonia
    Cortelezzi, Agostino
    [J]. BIODRUGS, 2016, 30 (03) : 219 - 223
  • [8] Anagrelide and Mutational Status in Essential Thrombocythemia
    Alessandra Iurlo
    Daniele Cattaneo
    Nicola Orofino
    Cristina Bucelli
    Sonia Fabris
    Agostino Cortelezzi
    [J]. BioDrugs, 2016, 30 : 219 - 223
  • [9] Anagrelide for treatment of essential thrombocythemia (ET): A cost-effectiveness analysis.
    Weinberg, PD
    Golub, RM
    Bennett, CL
    [J]. BLOOD, 1998, 92 (10) : 423A - 423A
  • [10] Successful treatment of essential thrombocythemia with anagrelide in a child
    Hermann, J
    Fuchs, D
    Sauerbrey, A
    Hempel, L
    Zintl, F
    [J]. MEDICAL AND PEDIATRIC ONCOLOGY, 1998, 30 (06): : 367 - 370
12345